M Seyal, MD
Cardiovascular Disease · Clarksville, INNPI 1568458743
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,215 of the $83,042 with a category attached, or 74.9%. Amarin Pharma, Inc. accounts for 96.4% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $68,893 and has fallen 99.6% since, to $294 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $296.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$80K
- Novartis$455
- Novo Nordisk$283
- AstraZeneca$262
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$186
- Merck$180
- plus $2K from 29 others
What the payments were for
- Consulting fees$1,4252%
- Speaking & faculty fees$62,21575%
- Travel & lodging$13,71217%
- Food & beverage$5,6647%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 119 | $80,023 |
| Novartis | 23 | $455 |
| Novo Nordisk | 17 | $283 |
| AstraZeneca | 11 | $262 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $186 |
| Merck | 10 | $180 |
| Amgen | 11 | $174 |
| Sanofi-aventis U.S. LLC | 13 | $168 |
| Johnson & Johnson | 8 | $133 |
| GSK | 6 | $121 |
| Treace Medical Concepts, Inc. | 1 | $120 |
| Scpharmaceuticals Inc. | 1 | $119 |
| Boston Scientific | 2 | $104 |
| Pfizer | 6 | $97 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| IBSA Pharma Inc. | 4 | $57 |
| AbbVie | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Bayer | 3 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Lilly USA, LLC | 2 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Chiesi USA, Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$78,466
- ENTRESTO$121
- LAPIPLASTY SYSTEM 1$120
- FUROSCIX$119
- FARXIGA$113
How this compares
$83,042 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ranolazine ErRanolazine | 24 | $1,009 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 57 | $497 |
| Metoprolol Succinate | 48 | $494 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $450 |
| Atorvastatin Calcium | 34 | $225 |
| Losartan Potassium | 33 | $175 |
| Nitroglycerin | 18 | $171 |
| Carvedilol | 11 | $124 |
| Lisinopril | 12 | $92 |
| Amlodipine Besylate | 27 | $85 |
| ClopidogrelClopidogrel Bisulfate | 29 | $80 |
| Atenolol | 14 | $46 |
| Furosemide | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Clarksville
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.